Erythropoietic factor

Details Erythropoietic factor Erythropoietic factor

1988-05-27

1991-01-22

Schain, Howard E.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 12, 514 13, 530397, A61K 3702

Patent

active

049871218

ABSTRACT:
A method for treating anemia comprises administering an atrial natriuretic factor (ANF) alone or in combination with erythropoietin (Epo). The ANF potentiates the activity of Epo and causes production of erythroid progenitors, BFU-E and CFU-E, and as a consequence red blood cell production at greater levels than if Epo alone is present in the blood stream.

REFERENCES:
patent: 3033753 (1962-05-01), White et al.
patent: 4377513 (1983-03-01), Sugimoto et al.
patent: 4465624 (1984-08-01), Chiba et al.
patent: 4607023 (1986-08-01), Thibault et al.
patent: 4652549 (1987-03-01), Blaine
patent: 4663437 (1987-05-01), de Bold
patent: 4670540 (1987-06-01), Sahakibara
patent: 4721704 (1988-01-01), Chang et al.
patent: 4732889 (1988-03-01), Cynshi et al.
patent: 4757048 (1988-07-01), Lewicki et al.
patent: 4804650 (1989-02-01), Lewicki et al.
patent: 4824937 (1989-04-01), Deghenghi et al.
patent: 4861755 (1989-08-01), Breipohl et al.
Hill, N., et al., Chem. Abs. 108(21): 180890v, 1988.
Niskanen, E., et al., Biochem. Biophys. Res. Commun., 156(1):15-21, Oct. 1988.
See list of 23 documents on the information disclosure statement.

Affiliated with

Also associated with

Rating

Erythropoietic factor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Erythropoietic factor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietic factor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1554931